ストックスクリーナーアプリを入手
2.95
1.03%
0.03
アフターアワーズ：
2.66
-0.29
-9.83%
前日終値:
$2.92
開ける：
$2.9
24時間の取引高:
56,665
Relative Volume:
3.19
時価総額：
$6.30M
収益：
-
当期純損益:
$-9.64M
株価収益率:
-6.413
EPS:
-0.46
ネットキャッシュフロー:
$-10.11M
1週間 パフォーマンス:
-14.92%
1か月 パフォーマンス:
+28.82%
6か月 パフォーマンス:
-5.45%
1年 パフォーマンス:
-58.24%
1日の値動き範囲:
$2.7284
$3.0458
1週間の範囲:
$2.70
$3.49
52週間の値動き範囲:
$1.9201
$10.66
Gt Biopharma Inc Stock (GTBP) Company Profile
名前
Gt Biopharma Inc
セクター
電話
(800) 304-9888
住所
315 MONTGOMERY STREET, SAN FRANCISCO
GTBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| GTBP | 0.2846 | 0 | 0 | 0 | 0 | 0.00 |
| GOODO | 22.16 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.141 | 297.56M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.16 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.61 | 114.98M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.95 | 63.87M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-24 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-13 | 開始されました | B. Riley Securities | Buy |
| 2021-03-17 | 開始されました | ROTH Capital | Buy |
Gt Biopharma Inc (GTBP) 最新ニュース
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
GT Biopharma Inc. (GTBP) Quarterly 10-Q Report - Quartzy
GT Biopharma Reports Third Quarter 2024 Financial Results - The Manila Times
GT Biopharma Reports $3.4M Q3 Loss, Advances Key Clinical Trial Timeline | GTBP Stock News - StockTitan
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Hydrafacial Announces Glow Getter Scholarship Program in Support of Estheticians - Quantisnow
Nanobodies Market Forecast CAGR 24.1% Projected for Size, Growth, and Share 2024-2031 | Proteintech Group, - EIN News
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
GT Biopharma to Host Virtual KOL Event Showcasing its NK - GlobeNewswire
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 - StockTitan
GTBP stock touches 52-week low at $1.92 amid market challenges - Investing.com Australia
DekaBank Deutsche Girozentrale Sells 115,287 Shares of GT Biopharma, Inc. (NASDAQ:GTBP) - Defense World
GT Biopharma announces officer role change By Investing.com - Investing.com Australia
GT Biopharma announces officer role change - Investing.com India
Systemic Mastocytosis Market to Witness Growth by 2032 | AB - openPR
Nanobodies Market Set to Witness | Significant Growth by 2024-2031 | Proteintech Group, Inc., GT Biopharma, - EIN News
NK Cell Therapy Treatment Drugs, Clinical Trials, Emerging Therapies and Companies 2024 - openPR
GTBP stock touches 52-week low at $2.06 amid market challenges - Investing.com Australia
GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update - Defense World
GT Biopharma : Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference - Marketscreener.com
GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024 - MSN
Exponential Growth Expected for Nanobodies Market Expected to Expand at a Steady 2024-2031 - WhaTech
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
GTBP stock touches 52-week low at $2.2 amid market challenges - Investing.com India
Nanobodies Market Current Evaluation and Long-Term Growth - openPR
GTBP stock touches 52-week low at $2.52 amid market challenges - Investing.com
Anthony Cataldo Is Assembling The Team To Fight Cancer - Yahoo Canada Shine On
Cracking The Code: Understanding Analyst Reviews For Doximity - Quantisnow
Around the Helix: Cell and Gene Therapy Company Updates – July 17, 2024 - CGTLive™
Second-Generation NK Cell Engager Heading to Trial for CD33+ Leukemia - CGTLive™
NK Cell Therapy Pipeline 2024 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Sc - Barchart
NK Cell Therapy Pipeline 2024 | ImmunityBio, Cantargia, - openPR
Rithem Life Sciences Announces Formation of Board of Directors - Quantisnow
Gt Biopharma Inc (GTBP) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):